View in EDS

Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.

Saved in:
Bibliographic Details
Title: Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
Authors: Cao J; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Zhu Z; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Wang H; Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA., Nichols TC; Drug Safety Research and Development, Pfizer Inc., San Diego, CA, 92121, USA., Lui GYL; Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA., Deng S; Biostatistics, La Jolla Laboratories, Pfizer Inc., San Diego, CA, 92121, USA., Rejto PA; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., VanArsdale T; Tumor Cell Biology, Oncology Research and Development, Pfizer Inc., San Diego, CA, 92121, USA., Hardwick JS; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Weinrich SL; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA., Wei P; Oncology Translational Research, Pfizer Inc., San Diego, CA, 92121, USA. ping.wei@pfizer.com.
Source: Oncogene [Oncogene] 2019 May; Vol. 38 (21), pp. 4125-4141. Date of Electronic Publication: 2019 Jan 30.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5594 (Electronic) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5594
DOI:10.1038/s41388-019-0708-7